Lisata Therapeutics funds MAR programs with $1,491.37 Series C

Lisata Therapeutics raised new financing via Series C non-voting convertible preferred shares to fund MAR001/005 and MAR002 programs, including planned Phase 2b in severe hypertriglyceridemia and Phase 2 in acromegaly, with topline data due Q4 2027.